Conclusions
HSDD, penile tumescence, low sexual desire
This randomized clinical trial provides the first clinical evidence to date showing that kisspeptin administration in men with low sexual desire (HSDD) modulates sexual brain activity as well as markedly increases penile tumescence in response to sexual stimuli (by up to 56% more than placebo) and associated behavioral measures of sexual desire and arousal. Taken together, our data suggest that pharmacological use of kisspeptin-based therapeutics may offer the first safe and much-needed clinical strategy for men with HSDD and low sexual desire more broadly.